SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT01752933
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
SGI-110
Sponsor
Astex Pharmaceuticals, Inc.